ANSWER: B

Rationale:

Mature ET-1 production requires two sequential enzymatic cleavages. Furin, a ubiquitous proprotein convertase, cleaves the signal peptide and C-terminus of the 212-amino-acid preproendothelin-1 to yield big ET-1, a 38-amino-acid biologically inactive intermediate. ECE-1 (endothelin-converting enzyme-1), a membrane-bound zinc metallopeptidase expressed on the surface of vascular endothelial cells, then cleaves big ET-1 specifically at the Trp21-Val22 bond to produce the mature 21-amino-acid ET-1 peptide. ECE-1 is concentrated in the pulmonary vasculature, which serves as the primary site of ET-1 production and processing; the lungs extract a significant fraction of circulating big ET-1 on first pass, making pulmonary endothelial ECE-1 the rate-limiting step in systemic ET-1 generation.

• Option A: Option A reverses the correct enzymatic sequence. ECE-1 does not act on preproendothelin-1 — that initial cleavage is performed by furin. ECE-1 acts downstream on big ET-1 specifically.
• Option C: Option C is incorrect because the biosynthetic pathway is a two-step sequential process. Furin produces big ET-1 as an obligate inactive intermediate; it does not generate mature ET-1 directly.
• Option D: Option D is incorrect on two counts: furin rather than ECE-1 performs the initial preproendothelin-1 cleavage, and the two enzymatic steps are not performed by two molecules of the same enzyme.
• Option E: Option E is incorrect. Angiotensin-converting enzyme plays no role in ET-1 biosynthesis. ACE cleaves angiotensin I to angiotensin II and degrades bradykinin; it is a distinct enzyme family from ECE-1 and does not process big ET-1.

ANSWER: D

Rationale:

ETA receptors are expressed primarily on vascular smooth muscle cells and cardiac myocytes. Their principal signaling mechanism involves coupling to Gq, which activates phospholipase C (PLC, an enzyme that cleaves the membrane phospholipid PIP2). PLC generates two second messengers: inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds receptors on the sarcoplasmic reticulum and releases stored calcium into the cytoplasm, initiating contraction. DAG activates protein kinase C (PKC), which phosphorylates contractile regulatory proteins and sensitizes the contractile apparatus, producing a prolonged vasoconstrictive response. ETA also couples to Gi to inhibit adenylyl cyclase, further reducing cAMP-dependent vasodilatory signaling. The sustained nature of ETA-mediated vasoconstriction — lasting hours after a single ET-1 exposure — reflects both the IP3-dependent calcium release and the PKC-mediated sensitization of the contractile machinery. ETA activation also drives mitogenesis and pro-fibrotic signaling, contributing to the vascular remodeling seen in PAH (pulmonary arterial hypertension).

• Option A: Option A incorrectly describes Gs-coupled receptor signaling producing vasodilation — the opposite of ETA's functional effect. ETA does not couple to Gs and does not increase cAMP; this signaling profile describes beta-adrenergic or prostacyclin receptor activation.
• Option B: Option B incorrectly attributes ETA signaling to Gi-mediated potassium channel opening. While ETA does couple to Gi to inhibit adenylyl cyclase, the primary vasoconstrictive mechanism proceeds through Gq and PLC, not through potassium channel hyperpolarization.
• Option C: Option C incorrectly omits the Gq/PLC pathway: while Rho-kinase does contribute to ETA-mediated calcium sensitization, stating that PLC is not engaged is incorrect. The Gq-PLC-IP3-DAG pathway is the primary established ETA signaling mechanism; excluding it produces an incomplete and misleading description.
• Option E: Option E incorrectly states that ETA couples to Gs. ETA receptors do not couple to Gs. The coupling profile of ETA is Gq (primary, producing vasoconstriction) and Gi (secondary, inhibiting adenylyl cyclase) — not Gs.

ANSWER: A

Rationale:

ETB receptors on vascular endothelial cells mediate two important counter-regulatory functions that oppose ETA-driven vasoconstriction and smooth muscle proliferation. First, endothelial ETB activation stimulates endothelial nitric oxide synthase (eNOS), increasing nitric oxide (NO) production; NO diffuses to adjacent vascular smooth muscle cells and activates soluble guanylate cyclase, raising cGMP (cyclic guanosine monophosphate) and producing vasodilation. Second, endothelial ETB activation stimulates cyclooxygenase (COX)-mediated production of prostacyclin (PGI2), which acts on smooth muscle IP receptors to raise cAMP and further promote relaxation. These two vasodilatory mediators represent the principal counter-regulatory mechanism through which endothelial ETB activity opposes the potent vasoconstriction and mitogenesis driven by ETA. This counter-regulatory function is one of the reasons the choice between selective ETA antagonism and dual ETA/ETB antagonism in PAH (pulmonary arterial hypertension) therapy has been pharmacologically debated.

• Option B: Option B incorrectly assigns ETA-type Gq/PLC signaling to endothelial ETB. ETB on endothelial cells does not amplify vasoconstriction; the vasoconstrictive ETB-mediated signaling through a mechanism similar to ETA occurs on vascular smooth muscle ETB, not on endothelial ETB.
• Option C: Option C is incorrect. Endothelial ETB receptors are functionally active and signal through established pathways to produce NO and PGI2. They also mediate receptor-mediated ET-1 internalization and lysosomal degradation, which is a genuine clearance function — but this is active receptor-mediated uptake, not passive sequestration by an inactive receptor.
• Option D: Option D describes the opposite of actual ETB endothelial function. ETB activation on endothelial cells enhances eNOS activity; it does not inhibit it. Phosphorylation at Thr495 is an inhibitory eNOS modification associated with other signaling contexts, not ETB activation.
• Option E: Option E is incorrect. Endothelial ETB does not couple exclusively to Gi, and its primary functional consequences — eNOS-derived NO and COX-derived PGI2 production — are vasodilatory, not vasoconstrictive. ETB on smooth muscle cells is the subpopulation that mediates vasoconstriction.

ANSWER: C

Rationale:

Endothelial ETB receptors serve as a major clearance mechanism for circulating ET-1 through receptor-mediated internalization: ET-1 binds the ETB receptor on the endothelial cell surface, the receptor-ligand complex is internalized via endocytosis, and ET-1 is delivered to lysosomes for proteolytic degradation. This clearance function is quantitatively substantial — approximately 50% of circulating ET-1 is cleared by lung ETB receptors on each pass through the pulmonary circulation, making the pulmonary vasculature not only the primary site of ET-1 synthesis but also a dominant site of ET-1 elimination. This pharmacological reality has direct clinical relevance: dual ETA/ETB antagonists such as bosentan block ETB-mediated clearance and thereby raise plasma ET-1 levels by 100–200% above baseline during therapy. This elevation in measured ET-1 levels during bosentan treatment does not indicate disease worsening — it is a pharmacodynamic consequence of ETB blockade impairing clearance. The selective ETA antagonist ambrisentan, by contrast, preserves ETB-mediated clearance and raises ET-1 levels less dramatically.

• Option A: Option A incorrectly underestimates the clearance capacity (approximately 10% vs. the correct approximately 50%) and incorrectly describes the mechanism as passive diffusion. ETB-mediated clearance is an active, receptor-dependent process requiring ligand binding and endocytosis, not passive diffusion.
• Option B: Option B is incorrect. The lung, not the liver, is the dominant site of ET-1 clearance from the circulation. Pulmonary endothelial ETB-mediated internalization accounts for approximately 50% of ET-1 removal per pass and is the primary clearance pathway, not an ancillary one.
• Option D: Option D is incorrect in asserting that ETB-mediated clearance is confined to the systemic venous circulation and that the lungs are irrelevant. The pulmonary endothelial ETB population is quantitatively the most important ET-1 clearance site in the body.
• Option E: Option E incorrectly attributes ET-1 clearance to neprilysin-mediated extracellular proteolysis. Neprilysin cleaves other vasoactive peptides including natriuretic peptides and enkephalins; ET-1 clearance by endothelial ETB proceeds through receptor-mediated internalization and lysosomal degradation, not extracellular neprilysin activity.

ANSWER: E

Rationale:

ETA and ETB receptors are distinguished by their ligand selectivity profiles. ETA receptors have high affinity for ET-1 and ET-2 but low affinity for ET-3; this selectivity means ET-3 does not efficiently activate the ETA-mediated vasoconstriction and mitogenesis that drive PAH (pulmonary arterial hypertension) pathophysiology. ETB receptors, by contrast, bind all three endothelin isoforms — ET-1, ET-2, and ET-3 — with comparable affinity; this non-selective ligand binding profile allows ET-3 to activate ETB-mediated vasodilation and ET-1 clearance on endothelial cells. This receptor-subtype ligand selectivity difference is pharmacologically important: ET-3 can activate endothelial ETB without activating ETA, meaning it has a net vasodilatory rather than vasoconstrictive effect despite being a member of the same peptide family as ET-1. Bosentan blocks ETA with approximately 20-fold selectivity over ETB (Ki approximately 4.7 nM for ETA vs. 95 nM for ETB), consistent with ETA being the primary pharmacological target for vasoconstriction antagonism.

• Option A: Option A is incorrect. ETA and ETB receptor subtypes have clearly distinct ligand selectivity profiles, and this selectivity is directly relevant to pharmacological targeting. ETA does not bind ET-3 with high affinity, which distinguishes it from ETB.
• Option B: Option B inverts the correct ligand selectivity. ET-3 is not a high-affinity ETA ligand; it is the isoform to which ETA has low affinity. ET-1 is the primary high-affinity ETA agonist and the dominant endogenous ET isoform in vascular biology.
• Option C: Option C is incorrect on both counts. ETA receptors bind ET-1 (and ET-2) with high affinity — ET-1 is the primary ETA ligand, not exclusive to ETB. ETB receptors bind all three isoforms, not exclusively ET-1.
• Option D: Option D overstates the correctness of its description: while it correctly identifies ET-1 selectivity and ETB ligand breadth, it inaccurately characterizes ETA affinity for ET-2 as only "moderate." ETA has high affinity for both ET-1 and ET-2; Option E is the more precise and complete correct statement.

ANSWER: B

Rationale:

ECE-1 is an attractive target because inhibiting it would prevent ET-1 formation from all upstream big ET-1, circumventing the need to antagonize individual receptor subtypes. However, ECE-1 is not an ET-1-specific enzyme — it cleaves multiple biologically important peptide substrates including bradykinin and substance P. When ECE-1 is inhibited, bradykinin accumulates because its normal ECE-1-mediated degradation is impaired; bradykinin excess causes angioedema, a potentially life-threatening adverse effect also seen with ACE inhibitors through the same bradykinin accumulation mechanism. Substance P accumulation from ECE-1 inhibition causes increased neurotransmission-related effects. These off-target consequences have prevented ECE-1 inhibitors from reaching clinical use despite their conceptual appeal. The current pharmacological approach for PAH therefore targets downstream receptor antagonism — accepting continued ET-1 synthesis in exchange for greater selectivity and an acceptable safety profile. No ECE-1 inhibitor is currently approved for any clinical indication.

• Option A: Option A is incorrect. ECE-1 is not redundantly covered by other enzymes that maintain full ET-1 production in the face of complete ECE-1 blockade. The failure of ECE-1 inhibitors to enter clinical use was not due to inadequate pharmacodynamic effect but rather to unacceptable off-target toxicity from non-ET-1 substrate accumulation.
• Option C: Option C is incorrect. ECE-1 is a membrane-bound zinc metallopeptidase expressed on the surface of vascular endothelial cells — it is a cell-surface enzyme, not an intracellular endoplasmic reticulum-resident enzyme, and is therefore accessible to systemically administered inhibitors.
• Option D: Option D describes a mechanism not established for ECE-1 inhibitors. Rebound preproendothelin-1 gene upregulation sufficient to overcome enzyme inhibition has not been reported as the primary obstacle to ECE-1 inhibitor development; the established barrier is off-target substrate accumulation.
• Option E: Option E is incorrect. ECE-1 inhibitors did not fail because ERA clinical data emerged and made them comparatively unnecessary. They failed to enter clinical development because of off-target safety problems identified in preclinical and early clinical studies — the two drug classes were not in a comparative competition where one displaced the other based on efficacy data.

ANSWER: D

Rationale:

Despite being produced by endothelial cells lining the vascular lumen, ET-1 is secreted predominantly abluminally — that is, toward the underlying vascular smooth muscle rather than into the bloodstream. This directional secretion gives ET-1 a primarily paracrine mode of action: it acts locally on adjacent smooth muscle cells rather than circulating as a systemic endocrine hormone. As a consequence, circulating plasma ET-1 levels measured in blood samples substantially underestimate the true local concentrations of ET-1 acting on smooth muscle ETA receptors in the vascular wall. This distinction matters clinically: in PAH (pulmonary arterial hypertension), plasma ET-1 levels are markedly elevated (often three to ten times above normal), but even these elevated plasma levels are thought to reflect overflow from a locally concentrated paracrine system rather than primary endocrine signaling. The paracrine secretion pattern also explains why ET-1 has such potent and sustained local vasoconstrictive effects despite relatively modest circulating concentrations in normal physiology.

• Option A: Option A incorrectly characterizes ET-1 as a systemic circulating hormone acting on distant vascular beds. While some ET-1 enters the circulation, ET-1's primary mode of action is paracrine — abluminal secretion toward adjacent smooth muscle — not endocrine transport to distant targets.
• Option B: Option B incorrectly implies equal bidirectional secretion. The predominant direction of ET-1 secretion is abluminal (paracrine). While local factors such as hypoxia and shear stress regulate ET-1 production, they do not convert its primary secretion from abluminal to luminal.
• Option C: Option C incorrectly states that ET-1 is exclusively stored in Weibel-Palade bodies and released into the bloodstream. While ET-1 is stored in Weibel-Palade bodies and acute stimuli can trigger its release, the primary secretory pathway is constitutive abluminal release toward smooth muscle in the paracrine mode, not acute exocytotic luminal release.
• Option E: Option E is incorrect. ET-1 is not rapidly inactivated before reaching smooth muscle. The abluminal secretion ensures high local concentrations at the smooth muscle target; ET-1 is not degraded by extracellular matrix proteases at a rate that would require continuously elevated synthesis to compensate. The duration of ET-1's vasoconstrictor action is sustained, lasting hours after a single pulse exposure.

ANSWER: A

Rationale:

Plasma ET-1 levels in PAH are markedly elevated — typically three to ten times above normal values — reflecting pathological overproduction by dysfunctional pulmonary endothelium combined with impaired ETB-mediated clearance. The magnitude of ET-1 elevation correlates with hemodynamic severity as measured by right heart catheterization: patients with higher mean pulmonary arterial pressures (mPAP) and higher pulmonary vascular resistance (PVR) tend to have greater ET-1 elevations. ET-1 elevation also correlates with prognosis — higher plasma ET-1 levels are associated with worse survival in PAH cohort studies. This pathological ET-1 overproduction arises from factors including hypoxia, shear stress, inflammatory cytokines, and oxidative stress acting on pulmonary endothelial cells to upregulate preproendothelin-1 gene transcription, while simultaneously impairing ETB-mediated ET-1 clearance, creating a dual mechanism for net ET-1 accumulation. The strong correlation between ET-1 levels and both hemodynamic parameters and clinical outcome provided the foundational rationale for developing ERA therapy in PAH.

• Option B: Option B incorrectly represents the magnitude of ET-1 elevation in PAH. Plasma ET-1 levels in PAH are three to ten times above normal — not merely a mild elevation of less than twofold. While ET-1 is primarily a paracrine mediator, its excess in PAH is sufficient to produce markedly abnormal circulating levels.
• Option C: Option C is incorrect. ET-1 levels are elevated, not suppressed, in PAH. There is no adaptive compensatory suppression of ET-1 in response to elevated pulmonary arterial pressure; the opposite occurs — elevated pressure and endothelial dysfunction upregulate ET-1 production further.
• Option D: Option D is incorrect. Circulating ET-1 levels in PAH do correlate with hemodynamic severity. While plasma ET-1 is not routinely used as a standalone clinical monitoring biomarker in the way that BNP (brain natriuretic peptide) is, the correlation between ET-1 elevation and both mPAP and PVR is well established in the PAH literature.
• Option E: Option E incorrectly restricts the correlation to right ventricular hypertrophy volume and explicitly denies the correlation with PVR and mPAP. The established data show ET-1 elevation correlates with multiple hemodynamic parameters including PVR and mPAP directly, not solely with RV structural changes.

ANSWER: C

Rationale:

ERAs — bosentan, ambrisentan, and macitentan — are approved and guideline-recommended specifically for WHO Group 1 PAH (pulmonary arterial hypertension). Group 1 encompasses idiopathic PAH (the most common form without identifiable cause), heritable PAH (most commonly from BMPR2 gene mutations), drug- and toxin-induced PAH (associated with anorexigens, methamphetamine, and certain tyrosine kinase inhibitors including dasatinib), and PAH associated with connective tissue disease (systemic sclerosis predominating), congenital heart disease, HIV infection, and portal hypertension. These conditions share the common pathobiological mechanism of obliterative pulmonary arterial remodeling driven in part by ET-1 overproduction, making ERA therapy mechanistically rational. ERAs are generally not used in WHO Groups 2 through 5, where pulmonary hypertension is secondary to distinct mechanisms — left heart disease, lung disease, chronic thromboembolic disease, and unclear or multifactorial causes — and where ET-1 overproduction is not the primary driver.

• Option A: Option A incorrectly identifies WHO Group 3 (pulmonary hypertension due to lung disease/hypoxia) as the ERA indication group. ERAs are not approved for Group 3. Treating Group 3 with ERAs has not demonstrated benefit and can worsen outcomes by causing systemic vasodilation that aggravates hypoxemia.
• Option B: Option B is incorrect. ERAs are not approved or recommended across all five WHO groups. Their approval is specifically limited to Group 1 PAH. Using ERAs in groups where the underlying mechanism differs from Group 1 PAH pathobiology can cause harm — particularly in Group 2, where ERA therapy risks precipitating pulmonary edema.
• Option D: Option D incorrectly identifies WHO Group 4 (chronic thromboembolic pulmonary hypertension, CTEPH) as the primary ERA indication. While ET-1 contributes to some vascular remodeling in CTEPH, the first-line intervention for Group 4 is pulmonary endarterectomy or balloon pulmonary angioplasty, not ERA therapy. Riociguat is the approved medical therapy for inoperable CTEPH; ERAs are not a guideline-recommended Group 4 therapy.
• Option E: Option E is incorrect and describes a dangerous misuse of ERAs. WHO Group 2 pulmonary hypertension is due to left heart disease with elevated left-sided filling pressures. In this setting, ERA-mediated pulmonary vasodilation can reduce right ventricular afterload but unmask elevated left atrial pressure, precipitating flash pulmonary edema. This is precisely why ERA use in Group 2 is contraindicated — Option E's rationale inverts the actual clinical risk.

ANSWER: E

Rationale:

This patient has WHO Group 2 pulmonary hypertension — pulmonary hypertension secondary to left heart disease. The diagnostic hallmark distinguishing Group 2 from Group 1 PAH is the pulmonary capillary wedge pressure (PCWP): a PCWP above 15 mmHg indicates elevated left-sided filling pressures consistent with left heart disease as the driver of pulmonary hypertension. This patient's PCWP of 22 mmHg firmly places her in Group 2, not Group 1. In Group 2, the pulmonary hypertension is a consequence of elevated left atrial and pulmonary venous pressures — a fundamentally different mechanism from the obliterative pulmonary arterial remodeling of Group 1. ERA therapy in this setting is contraindicated because reducing pulmonary afterload with an ERA can improve right ventricular output but simultaneously deliver increased flow into a left heart that cannot accommodate it, dramatically raising pulmonary venous pressure and precipitating acute pulmonary edema. Before initiating ERA therapy, right heart catheterization is required to confirm hemodynamic Group 1 criteria (mPAP greater than 20 mmHg and PCWP at or below 15 mmHg) — this patient fails that criterion.

• Option A: Option A is incorrect. There is no pharmacodynamic threshold of mean pulmonary arterial pressure above which ERA therapy becomes ineffective. The contraindication in Group 2 disease is not related to ERA pharmacodynamics but to the underlying hemodynamic mechanism — elevated left-sided filling pressures that ERA therapy would worsen.
• Option B: Option B is incorrect. ET-1 levels can be elevated in heart failure and secondary pulmonary hypertension; they are not consistently suppressed. However, even if ET-1 were elevated, that would not justify ERA use in Group 2, because the mechanism of pulmonary hypertension is different and ERA therapy would be harmful regardless of ET-1 levels.
• Option C: Option C is incorrect. ERA pharmacokinetics and QT prolongation are not the basis for the Group 2 contraindication. ERA drugs (particularly bosentan and macitentan) do not carry significant QT prolongation risk, and their half-lives are manageable in heart failure patients. The contraindication is hemodynamic, not pharmacokinetic.
• Option D: Option D is incorrect. The rationale for the Group 2 ERA contraindication is not that the condition might resolve; it is that ERA therapy actively risks precipitating acute pulmonary edema. The concern is immediate hemodynamic harm, not a theoretical interaction with future left ventricular recovery assessment.

ANSWER: B

Rationale:

The current hemodynamic definition of PAH, updated in the 2022 ESC/ERS guidelines for pulmonary hypertension, requires three criteria confirmed by right heart catheterization: mean pulmonary arterial pressure (mPAP) greater than 20 mmHg at rest (revised downward from the prior threshold of greater than 25 mmHg), pulmonary arterial wedge pressure (PAWP, also called pulmonary capillary wedge pressure, PCWP) at or below 15 mmHg (to exclude left heart disease as the driver), and absence of identifiable secondary causes of pulmonary hypertension. Right heart catheterization is mandatory — echocardiography cannot replace it because echo-derived pressure estimates have wide confidence intervals and cannot measure wedge pressure. The PAWP criterion of 15 mmHg or below is the critical distinguishing threshold: above 15 mmHg places the patient in WHO Group 2 (pulmonary hypertension due to left heart disease), where ERA therapy is contraindicated. Pulmonary vascular resistance (PVR) greater than 2 Wood units is also part of the updated 2022 hemodynamic definition and supports the pre-capillary nature of PAH, though this was not listed in every prior iteration. Before initiating ERA therapy, right heart catheterization confirmation of these criteria is mandatory.

• Option A: Option A incorrectly states a PAWP greater than 15 mmHg as part of the PAH definition — that finding actually characterizes Group 2 disease, not Group 1 PAH. Additionally, echocardiography cannot substitute for right heart catheterization; invasive hemodynamic confirmation is required before ERA initiation.
• Option C: Option C incorrectly uses an outdated and non-standard mPAP threshold (greater than 30 mmHg at rest) and introduces an exercise criterion that is not part of the current WHO/ESC/ERS resting hemodynamic definition. The current threshold is mPAP greater than 20 mmHg at rest, not 30 mmHg.
• Option D: Option D incorrectly uses the transpulmonary gradient as the sole distinguishing criterion and incorrectly suggests that V/Q scanning can replace right heart catheterization. While V/Q scanning is essential for ruling out Group 4 thromboembolic disease, it does not replace right heart catheterization for PAH diagnosis.
• Option E: Option E incorrectly uses echocardiographic systolic pulmonary arterial pressure as the definitive diagnostic criterion. Echocardiography provides estimated, not measured, pressures and cannot measure wedge pressure; it is a screening tool. Right heart catheterization is required before initiating any PAH-specific therapy, regardless of which drug class is planned.

ANSWER: D

Rationale:

Bosentan is a dual ETA/ETB antagonist. Because it blocks ETB receptors — including the endothelial ETB receptors that normally mediate approximately 50% of circulating ET-1 clearance through receptor-mediated internalization and lysosomal degradation — bosentan impairs this clearance pathway. The result is an accumulation of plasma ET-1, which typically rises 100–200% above pre-treatment baseline levels during bosentan therapy. This elevation is a direct pharmacodynamic consequence of ETB blockade impairing ET-1 clearance; it does not represent disease progression, drug failure, or a pathological increase in ET-1 synthesis. Importantly, the therapeutic benefit of bosentan derives from its ETA blockade (reducing vasoconstriction and smooth muscle proliferation), and this benefit occurs despite — and is in some ways masked by — the elevated measured ET-1 levels. The selective ETA antagonist ambrisentan, which preserves ETB-mediated clearance, raises ET-1 levels much less because pulmonary ETB clearance remains functional. Elevated ET-1 during bosentan therapy should be interpreted as confirmation of drug exposure and ETB engagement, not as evidence of disease worsening.

• Option A: Option A is incorrect and represents a dangerous clinical misinterpretation. Elevated plasma ET-1 during bosentan therapy is a pharmacodynamic consequence of ETB blockade impairing clearance, not a marker of inadequate receptor blockade or disease progression warranting dose escalation. Treating this finding by doubling the dose would expose the patient to unnecessary toxicity.
• Option B: Option B incorrectly conflates two separate bosentan pharmacological phenomena. Bosentan autoinduction is real — CYP3A4/2C9 induction reduces steady-state plasma bosentan concentrations by approximately 50% at 4–8 weeks, which is why dose escalation from 62.5 mg to 125 mg twice daily is standard. However, ET-1 elevation during bosentan therapy is not caused by autoinduction reducing drug levels; it is caused by ETB blockade impairing clearance, which occurs even at therapeutic bosentan concentrations.
• Option C: Option C is incorrect. ET-1 elevation during bosentan therapy is not an indicator of hypersensitivity reaction. Hypersensitivity to bosentan would manifest with characteristic features (rash, eosinophilia, systemic symptoms) and would not selectively upregulate preproendothelin-1 transcription without other clinical signs. The ET-1 elevation mechanism is purely pharmacodynamic.
• Option E: Option E incorrectly attributes the ET-1 elevation to a reflex homeostatic feedback increase in preproendothelin-1 gene transcription triggered by excessive ETB blockade. The actual mechanism is impaired clearance due to ETB receptor blockade on endothelial cells, not upregulated synthesis. The finding is not restricted to treatment responders; it is a universal pharmacodynamic consequence of dual ERA use.

ANSWER: A

Rationale:

Ambrisentan is a propanoic acid derivative with approximately 4,000-fold selectivity for ETA over ETB receptors — a substantially higher degree of ETA selectivity than bosentan, which has only approximately 20-fold ETA preference. This high selectivity for ETA means ambrisentan does not significantly antagonize endothelial ETB receptors. As a result, ETB-mediated ET-1 clearance by the pulmonary endothelium remains largely intact during ambrisentan therapy, and ET-1-stimulated endothelial NO and prostacyclin production through endothelial ETB continues to function. The preservation of ETB-mediated clearance means plasma ET-1 levels rise much less during ambrisentan therapy compared to the 100–200% rise seen with bosentan. Clinically, the high ETA selectivity of ambrisentan was the theoretical basis for its development — preserving beneficial ETB endothelial functions while blocking the pathological ETA-mediated vasoconstriction and smooth muscle proliferation driving PAH. While this selectivity advantage did not translate into demonstrably superior clinical outcomes versus dual ERAs in randomized trials, it did correlate with a markedly superior hepatic safety profile, leading to removal of mandatory monthly liver function monitoring requirements for ambrisentan.

• Option B: Option B incorrectly describes ambrisentan as having a similar selectivity ratio to bosentan and attributes its mechanism to non-competitive rather than competitive binding. Ambrisentan's approximately 4,000-fold ETA selectivity versus bosentan's approximately 20-fold selectivity is a major distinguishing pharmacological characteristic, not a minor similarity.
• Option C: Option C inverts the receptor selectivity: ambrisentan is an ETA-selective agent with approximately 4,000-fold preference for ETA, not an ETB-selective agent. An ETB-selective antagonist would block ET-1 clearance and impair endothelial vasodilation, the opposite of ambrisentan's pharmacological profile.
• Option D: Option D is incorrect. Ambrisentan is not non-selective; it has approximately 4,000-fold selectivity for ETA over ETB. Its clinical advantages include both the receptor selectivity profile and the favorable metabolic and hepatic safety profile. Stating that receptor selectivity is irrelevant to its clinical differentiation from bosentan is inaccurate.
• Option E: Option E incorrectly underestimates ambrisentan's ETA selectivity. Approximately 500-fold is a substantial underestimate of the approximately 4,000-fold selectivity actually measured for ambrisentan. This quantitative difference is clinically significant because it determines the degree to which ETB-mediated clearance is preserved.

ANSWER: C

Rationale:

Macitentan is structurally derived from bosentan but was engineered with modifications that produce tissue-targeting pharmacology. Two key innovations distinguish it. First, enhanced lipophilicity allows macitentan to partition into tissue compartments including vascular smooth muscle more effectively than bosentan, increasing its local concentration at the target receptor site beyond what plasma levels alone would predict. Second, macitentan has slower receptor dissociation kinetics — a very slow off-rate that makes its receptor binding functionally non-competitive at clinical concentrations. This slow off-rate means receptor occupancy is maintained for a duration that exceeds the drug's plasma half-life (approximately 16 hours), providing sustained ETA and ETB blockade throughout the once-daily dosing interval. The active metabolite ACT-132577, with a half-life of approximately 48 hours, contributes additively to overall receptor occupancy, further extending pharmacological coverage. These tissue-targeting properties provided the rationale for testing macitentan in a long-term morbidity-mortality endpoint trial (SERAPHIN), which demonstrated 45% reduction in the composite primary endpoint of clinical worsening or death.

• Option A: Option A incorrectly attributes macitentan's key innovation to ultra-high ETA selectivity surpassing ambrisentan. Macitentan is actually a dual ETA/ETB antagonist, not a selective ETA antagonist; its distinguishing pharmacological feature is tissue targeting through lipophilicity and slow receptor off-rate kinetics, not receptor selectivity.
• Option B: Option B incorrectly attributes an ECE-1 inhibition mechanism to macitentan. Macitentan does not inhibit ECE-1. It is a receptor-level antagonist (ETA and ETB) only. ECE-1 inhibitors remain without a clinically approved representative as a class.
• Option D: Option D incorrectly describes a prodrug strategy activated by pulmonary endothelial enzymes. Macitentan is an active drug — it is not a prodrug requiring local activation. Its tissue-targeting mechanism is pharmacokinetic (enhanced lipophilicity and slow receptor off-rate), not metabolic activation by local enzymes.
• Option E: Option E incorrectly describes macitentan as producing irreversible covalent receptor binding. Macitentan's binding is non-competitive with a slow off-rate but is not covalent or irreversible. Covalent binding would present significant safety concerns and would not be described as a therapeutic advantage; the slow off-rate kinetics produce sustained pharmacological effect without permanent receptor alkylation.

ANSWER: E

Rationale:

Bosentan is not merely a substrate of CYP3A4 and CYP2C9 — it is a potent inducer of both enzymes. Critically, bosentan induces its own metabolism, a phenomenon known as autoinduction. Over the first 4–8 weeks of therapy, as CYP3A4 and CYP2C9 enzyme protein is upregulated in response to bosentan exposure, the metabolic clearance of bosentan itself accelerates. The result is that steady-state plasma bosentan concentrations at the 62.5 mg twice-daily dose fall by approximately 50% between the initial weeks and the steady-state autoinduced state — meaning the drug progressively clears itself more rapidly over time. The dose escalation from 62.5 mg to 125 mg twice daily at 4 weeks is specifically designed to compensate for this reduction in plasma concentrations caused by autoinduction, maintaining adequate receptor occupancy as CYP induction reaches its plateau. This autoinduction also has important drug interaction implications: because bosentan induces CYP3A4 and CYP2C9, it simultaneously reduces plasma concentrations of co-administered CYP3A4 and CYP2C9 substrates including sildenafil, warfarin, oral contraceptives, simvastatin, and cyclosporine.

• Option A: Option A describes a saturable hepatic first-pass extraction model that does not apply to bosentan's known pharmacokinetics. Bosentan's dose escalation strategy is driven by autoinduction, not by saturation of first-pass extraction at low doses.
• Option B: Option B incorrectly attributes the dosing strategy to P-gp inhibition by bosentan at higher doses. Bosentan is not primarily characterized by P-gp inhibition affecting its own absorption kinetics. Ambrisentan (not bosentan) is a P-gp substrate; bosentan's pharmacokinetics are dominated by hepatic CYP-mediated metabolism and autoinduction.
• Option C: Option C incorrectly describes bosentan as a CYP2C9 inhibitor. Bosentan is a CYP2C9 inducer, not an inhibitor. The distinction is clinically critical: inhibition would raise co-administered drug levels, whereas induction (bosentan's actual effect) lowers them.
• Option D: Option D incorrectly identifies renal clearance as the primary elimination route for bosentan. Bosentan undergoes hepatic metabolism (CYP3A4 and CYP2C9) with biliary excretion as the primary elimination route; renal excretion is not the major clearance pathway, and renal function assessment does not drive the initial dose strategy.

ANSWER: B

Rationale:

The bosentan-cyclosporine interaction is bidirectional and clinically severe, making the combination contraindicated. The interaction operates through two simultaneous mechanisms. First, cyclosporine markedly raises plasma bosentan concentrations — cyclosporine inhibits organic anion-transporting polypeptides (OATPs, also called OATPs), the hepatic uptake transporters that mediate bosentan's hepatic extraction, and also competes with bosentan for CYP3A4-mediated metabolism; the combined effect is a several-fold increase in bosentan exposure that dramatically increases bosentan hepatotoxicity risk. Second, bosentan simultaneously induces CYP3A4, the primary enzyme responsible for cyclosporine metabolism, reducing cyclosporine plasma concentrations by approximately 50%; in a transplant recipient, this degree of cyclosporine reduction risks acute rejection and graft loss. The combination therefore creates two simultaneous serious hazards — bosentan toxicity and transplant rejection — making it absolutely contraindicated. In a transplant patient requiring ERA therapy, ambrisentan or macitentan should be considered instead, as they do not induce CYP enzymes and have substantially less interaction potential with cyclosporine.

• Option A: Option A incorrectly underestimates the severity and mechanism of the interaction. The bosentan-cyclosporine interaction is not a mild renal tubular secretion inhibition manageable with dose reduction; it is a severe bidirectional pharmacokinetic interaction involving both OATP inhibition and CYP3A4 induction that makes the combination absolutely contraindicated.
• Option C: Option C inverts bosentan's CYP effect: bosentan is a CYP3A4 inducer, not an inhibitor. Induction reduces cyclosporine levels (increasing rejection risk), not raises them. Additionally, classifying this interaction as manageable with modest monitoring understates its severity — the combination is contraindicated, not merely dose-adjustable.
• Option D: Option D fabricates a calcineurin inhibition mechanism for bosentan that does not exist. Bosentan is an endothelin receptor antagonist with no calcineurin inhibitory activity. There is no therapeutic rationale for combining bosentan with cyclosporine to reduce calcineurin inhibitor dosing.
• Option E: Option E incorrectly describes the interaction as unidirectional. Cyclosporine does substantially raise bosentan concentrations through OATP inhibition and CYP3A4 competition — bosentan's hepatic extraction is not so high as to make OATP-mediated uptake irrelevant. The bidirectionality of this interaction is precisely what makes it so dangerous and the combination absolutely contraindicated.

ANSWER: D

Rationale:

Bosentan is a potent CYP3A4 and CYP2C9 inducer. Combined oral contraceptives (estrogen-progestin formulations) rely heavily on CYP3A4-mediated metabolism for their hepatic clearance. When bosentan upregulates CYP3A4 activity — including in the gut wall and liver — the metabolic clearance of both the estrogen component (typically ethinyl estradiol) and the progestin component is substantially increased, reducing their plasma concentrations and impairing the ovarian suppression and endometrial effects that provide contraceptive efficacy. The degree of CYP3A4 induction by bosentan is sufficient to reduce oral contraceptive plasma levels to the extent that contraceptive failure becomes a clinically meaningful risk. Because all three ERAs require REMS enrollment with mandatory monthly pregnancy testing (given the absolute teratogenicity contraindication of the entire ERA class), and because bosentan specifically compromises hormonal contraceptive efficacy through CYP induction, REMS requirements for bosentan mandate that women of childbearing potential use at least two reliable forms of contraception — typically combining a hormonal method with barrier contraception. Ambrisentan and macitentan do not significantly induce oral contraceptive metabolism but still require REMS enrollment and two contraceptive methods.

• Option A: Option A incorrectly describes bosentan as a UGT1A inhibitor that raises progestin levels. Bosentan is a CYP inducer, not a UGT inhibitor. The consequence of bosentan's CYP induction is reduced (not elevated) oral contraceptive hormone levels, leading to contraceptive failure through inadequate ovarian suppression.
• Option B: Option B fabricates a progesterone receptor activation mechanism for bosentan. Bosentan is an endothelin receptor antagonist with no affinity for sex hormone receptors. It affects oral contraceptive efficacy solely through CYP3A4-mediated metabolic induction, not through direct hormonal receptor competition.
• Option C: Option C describes a chelation mechanism that does not apply to bosentan. Bosentan is not a chelating agent, and its effect on oral contraceptive efficacy is entirely pharmacokinetic — CYP3A4 induction increasing metabolic clearance — not a GI absorption interaction related to mineral binding.
• Option E: Option E inverts bosentan's effect on OATP transporters. Bosentan is actually a substrate for hepatic OATPs (and cyclosporine's ability to inhibit OATP uptake of bosentan is why that combination is contraindicated). Bosentan itself does not inhibit OATP transporters involved in oral contraceptive enterohepatic recirculation; this is not the mechanism by which it compromises contraceptive efficacy.

ANSWER: A

Rationale:

The ARIES-1 and ARIES-2 trials (Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-blind, placebo-controlled, multicenter, Efficacy Studies) randomized 394 patients with PAH to ambrisentan 5 mg/day, 10 mg/day, or placebo, with the primary endpoint of change in 6-minute walk distance (6MWD) at 12 weeks — a standard short-term functional endpoint used in PAH trials at that time. Both ambrisentan doses produced statistically significant improvements in 6MWD compared to placebo, and both significantly delayed time to clinical worsening as a key secondary endpoint. A critical finding with immediate clinical practice implications was ambrisentan's hepatic safety profile: the rate of elevated liver aminotransferases in ambrisentan-treated patients was similar to placebo rates and substantially lower than rates observed in bosentan-treated patients from historical comparisons. This superior hepatic safety record led directly to removal of the mandatory monthly liver function test monitoring requirement that had previously applied to all ERA therapies as a class. For ambrisentan, baseline liver function tests are obtained, but the monthly monitoring burden that bosentan requires is not imposed.

• Option B: Option B describes the design and results of the SERAPHIN trial, which studied macitentan (not ambrisentan) using an event-driven composite morbidity-mortality endpoint over a median 115-week follow-up period. The ARIES trials used a shorter 12-week 6MWD endpoint, not the long-term composite endpoint design described.
• Option C: Option C describes the AMBITION trial design (ambrisentan plus tadalafil vs. monotherapy), which is a separate trial from ARIES. The ARIES trials were placebo-controlled trials establishing ambrisentan efficacy; the AMBITION trial established upfront combination therapy superiority.
• Option D: Option D incorrectly describes the ARIES trials as a head-to-head comparison between ambrisentan and bosentan. The ARIES trials compared ambrisentan to placebo; no direct head-to-head randomized comparison between ambrisentan and bosentan has established clinical superiority of either over the other based on primary endpoints.
• Option E: Option E incorrectly describes the ARIES trials as dose-finding pharmacokinetic studies with a once-weekly dosing outcome. The ARIES trials were phase III placebo-controlled efficacy trials. Ambrisentan is dosed once daily (5 mg or 10 mg), not once weekly; its once-daily dosing reflects its approximately 15-hour half-life and standard pharmacokinetic properties.

ANSWER: C

Rationale:

The SERAPHIN trial (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome) was a landmark in PAH trial methodology because it departed from the 12-week 6-minute walk distance endpoint used in prior ERA trials. SERAPHIN was event-driven — rather than following patients for a fixed short period and measuring a functional surrogate, it followed 742 PAH patients for a median of approximately 115 weeks until sufficient composite primary endpoint events accrued. The primary endpoint was time to first event of worsening PAH (defined as decrease in 6MWD, worsening WHO functional class, intravenous or subcutaneous PAH therapy initiation, or lung transplantation) or death. Macitentan 10 mg significantly reduced this morbidity-mortality composite endpoint by 45% versus placebo, expressed as a hazard ratio of 0.55 (97.5% confidence interval 0.39–0.76, p less than 0.001). Mortality as an isolated endpoint did not achieve statistical significance — a finding consistent with the trial being underpowered for mortality alone given the long survival of PAH patients even in the placebo arm. However, the composite morbidity-mortality data from SERAPHIN remain the most robust long-term efficacy evidence for any ERA, and they provided the basis for macitentan's approval.

• Option A: Option A incorrectly describes SERAPHIN as a 12-week 6MWD trial. SERAPHIN used a long-term event-driven composite morbidity-mortality endpoint design over a median follow-up of approximately 115 weeks. The 12-week 6MWD design was used in the ARIES trials for ambrisentan, not in SERAPHIN.
• Option B: Option B incorrectly describes SERAPHIN as an extension study of the ARIES trials comparing ambrisentan to macitentan. SERAPHIN was an independent randomized placebo-controlled trial designed specifically to evaluate macitentan; it was not derived from or linked to the ambrisentan ARIES program.
• Option D: Option D incorrectly describes SERAPHIN as a non-inferiority comparison of macitentan versus bosentan using pulmonary vascular resistance as the primary endpoint. SERAPHIN was a placebo-controlled superiority trial; it did not compare macitentan to bosentan head-to-head, and pulmonary vascular resistance was not the primary endpoint.
• Option E: Option E fabricates a pharmacokinetic-pharmacodynamic bridging study description and incorrectly attributes a once-weekly dosing regimen to macitentan. Macitentan is dosed once daily (10 mg), not once weekly. The contribution of ACT-132577 to total receptor occupancy does support once-daily dosing adequacy, but SERAPHIN was a clinical efficacy and outcomes trial, not a PK/PD bridging study.

ANSWER: E

Rationale:

Bosentan hepatotoxicity is caused by inhibition of BSEP (bile salt export pump), a canalicular ATP-binding cassette transporter on the bile-secreting surface of hepatocytes. BSEP is responsible for the active transport of conjugated bile salts from hepatocytes into the bile canaliculi — the rate-limiting step in biliary excretion of bile salts. When bosentan inhibits BSEP, bile salt secretion into bile is reduced, and bile salts accumulate within hepatocytes. Intrahepatic bile salt accumulation is directly cytotoxic to hepatocytes through detergent-like membrane disruption and mitochondrial dysfunction, producing a pattern of cholestatic hepatocyte injury rather than classic hepatocellular necrosis. This mechanism is dose-dependent and produces the characteristic dose-related aminotransferase elevations (predominantly ALT and AST) seen in approximately 10% of bosentan-treated patients. The injury is generally asymptomatic and reversible upon dose reduction or discontinuation. Ambrisentan and macitentan do not inhibit BSEP; their hepatotoxicity rates in controlled trials were comparable to placebo, which is why mandatory monthly liver function monitoring is not required for either agent. This mechanistic difference is clinically important in selecting ERA therapy for patients with pre-existing hepatic disease.

• Option A: Option A incorrectly attributes bosentan hepatotoxicity to mechanism-based CYP3A4 inactivation by a reactive metabolite causing hepatocellular necrosis. While bosentan does induce CYP3A4, it does not produce a reactive metabolite that causes CYP mechanism-based inactivation and hepatocyte necrosis. The established mechanism is BSEP inhibition and cholestatic injury, not CYP-mediated cytotoxicity. Furthermore, ambrisentan and macitentan do not cause the same type of injury.
• Option B: Option B incorrectly attributes bosentan hepatotoxicity to ischemic hepatitis through ETA blockade in hepatic portal venules. ETA receptor antagonism in the hepatic vasculature does not produce clinically significant ischemic hepatic injury; bosentan's hepatotoxicity is a direct transporter-mediated effect, not a vascular mechanism.
• Option C: Option C incorrectly attributes bosentan hepatotoxicity to an immune-mediated haptenization mechanism. Drug-induced immune hepatitis is a distinct entity from BSEP inhibition-mediated cholestatic injury. Bosentan's hepatotoxicity is dose-dependent and reversible — features more consistent with a metabolic/transporter mechanism than an immune-mediated one, which typically causes idiosyncratic irreversible injury.
• Option D: Option D incorrectly attributes bosentan hepatotoxicity to CYP2C9-mediated production of a glutathione-depleting toxic aldehyde metabolite. This describes a hepatotoxicity mechanism relevant to other drugs (such as acetaminophen, through CYP2E1) but does not apply to bosentan. Bosentan's hepatotoxicity is BSEP-mediated, and the risk is not specifically elevated in CYP2C9 poor metabolizers.

ANSWER: B

Rationale:

All three ERAs — bosentan (Tracleer REMS), ambrisentan (Letairis REMS), and macitentan (Opsumit REMS) — are enrolled in FDA REMS programs because of the class-wide absolute contraindication in pregnancy. The pharmacological rationale is mechanistically clear: ET-1 signaling through ETA and ETB receptors is required for normal embryonic cardiovascular development, particularly for septation of the cardiac outflow tract, formation of major vessel architecture, and craniofacial morphogenesis. ERA-mediated blockade of this developmental signaling in animal models produces severe and consistent malformations including cardiac septal defects, aortic arch abnormalities, and craniofacial and skeletal malformations; the pattern of injury is sufficiently severe and the mechanism sufficiently plausible in humans that ERA use in pregnancy is classified as absolutely contraindicated. REMS requirements for all three agents mandate monthly pregnancy testing for women of childbearing potential and require use of at least two reliable contraceptive methods simultaneously. Bosentan's additional CYP3A4 induction of oral contraceptive metabolism makes barrier contraception especially important for women on hormonal methods while taking bosentan specifically.

• Option A: Option A incorrectly identifies QT prolongation as the class-wide ERA safety concern requiring REMS. ERA drugs do not carry class-wide QT prolongation risk, and monthly ECG monitoring is not a REMS requirement for any of the three agents. QT prolongation REMS programs exist for other drug classes but not ERAs.
• Option C: Option C incorrectly identifies pulmonary fibrosis as a class-wide ERA adverse effect requiring REMS-mandated CT surveillance. ERA drugs do not cause pulmonary fibrosis; in fact, they are used to treat the fibrotic vascular remodeling of PAH. Annual CT scanning is not a REMS requirement for any ERA.
• Option D: Option D incorrectly states that monthly liver function testing is mandated equally across all three ERA REMS programs. This is incorrect: monthly LFT monitoring is required for bosentan (Tracleer REMS) due to its BSEP inhibition mechanism, but is not a mandatory requirement for ambrisentan (Letairis REMS) or macitentan (Opsumit REMS), whose hepatotoxicity rates are comparable to placebo. The three REMS programs differ in their monitoring requirements.
• Option E: Option E fabricates a paradoxical vasoconstriction risk during ERA initiation that is not an established class effect. ERAs do not cause paradoxical pulmonary vasoconstriction, and mandatory hospitalization for ERA initiation is not a REMS requirement. Hospitalization-based initiation with hemodynamic monitoring applies to certain other PAH therapies (particularly intravenous prostacyclin analogues), not to oral ERA therapy.

ANSWER: D

Rationale:

Peripheral edema and anemia are the two established class-wide adverse effects shared across bosentan, ambrisentan, and macitentan. Peripheral edema, affecting 5–17% of ERA-treated patients, reflects the pharmacological consequence of endothelin receptor antagonism in the renal vasculature: ET-1 normally acts on renal vascular receptors to influence renal hemodynamics and tubular sodium handling, and ERA-mediated blockade shifts the balance toward sodium retention and fluid accumulation. In PAH patients, peripheral edema due to ERA therapy must be clinically distinguished from right heart failure-related edema, which carries different prognostic implications and management priorities. Anemia — typically a hemoglobin reduction of approximately 1 g/dL from baseline — occurs in approximately 13% of bosentan-treated and approximately 8% of ambrisentan-treated patients. The mechanism is attributed to hemodilution secondary to the ERA-induced fluid retention and, potentially, to inhibition of ET-1's role in erythropoietin signaling in the kidney. These two class effects require monitoring across all ERA-treated patients regardless of agent selection, in addition to agent-specific monitoring requirements such as monthly LFTs for bosentan.

• Option A: Option A incorrectly identifies bronchospasm and systemic hypotension as the class-wide ERA adverse effects. While pulmonary vasodilation is the therapeutic goal of ERA use, significant systemic hypotension is not a prevalent class-wide adverse effect in clinical use. Bronchospasm is also not an established class-wide ERA adverse effect and does not reflect ETB blockade in airway smooth muscle in the clinical setting.
• Option B: Option B incorrectly identifies elevated serum creatinine and hyperkalemia as class-wide ERA effects. These adverse effects characterize RAAS inhibitors (ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists); they are not established class-wide consequences of ERA therapy. ERA drugs do not inhibit aldosterone or angiotensin signaling directly, and their renal effects produce sodium retention and edema (not hyperkalemia and creatinine elevation) as the clinical manifestation.
• Option C: Option C incorrectly identifies headache and flushing, which are vasodilation-related adverse effects that can occur with ERA therapy but are not the most clinically important class-wide effects requiring active monitoring and management. Peripheral edema and anemia are the established class-wide effects of clinical significance across all three agents.
• Option E: Option E incorrectly states that hepatic transaminase elevation and QT prolongation are class-wide effects occurring at equivalent rates across all three ERAs. Hepatotoxicity is an agent-specific concern for bosentan (BSEP inhibition mechanism); ambrisentan and macitentan have placebo-comparable hepatotoxicity rates. QT prolongation is not an established class-wide ERA adverse effect, and quarterly ECG surveillance is not a REMS requirement for ERA therapy.